Dianabol and Propranolol Interaction: Avoid | Peptide Database

Join others researching Ezetimibe — share findings, ask questions, and learn from real experiences Ezetimibe is a selective cholesterol absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the brush border of the small intestine, preventing dietary and biliary cholesterol from entering the bloodstream. Approved by the FDA in 2002, it occupies a unique niche among lipid-lowering agents by targeting intestinal cholesterol uptake rather than hepatic cholesterol synthesis. In the context of anabolic steroid use, ezetimibe has become a go-to ancillary compound for managing the dyslipidemia that accompanies many AAS cycles, particularly oral steroids like oxandrolone (Anavar) and stanozolol (Winstrol) that are notorious for crashing HDL cholesterol and elevating LDL. While statins remain the first-line treatment for hypercholesterolemia in the general population, ezetimibe is frequently used alone or stacked with a statin by steroid users seeking to mitigate cycle-induced lipid damage without adding yet another hepatotoxic compound to the mix. Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle. By blocking this transporter, ezetimibe reduces cholesterol delivery to the liver, which in turn upregulates hepatic LDL receptor expression to compensate for the reduced cholesterol supply. This upregulation increases LDL clearance from the bloodstream. The mechanism is entirely complementary to statins, which inhibit HMG-CoA reductase to reduce hepatic cholesterol synthesis. When the liver is deprived of cholesterol from both sources simultaneously, the LDL-lowering effect is significantly amplified. Ezetimibe undergoes glucuronidation in the intestinal wall and liver to form its active metabolite, ezetimibe-glucuronide, which is also pharmacologically active and participates in enterohepatic recirculation, contributing to the drug's prolonged duration of action.

Winlevi (clascoterone cream 1%) is FDA-approved for the topical treatment of acne vulgaris in patients 12 years and older. Phase 3 trials demonstrated statistically significant reductions in inflammatory and non-inflammatory lesion counts compared to vehicle, with an Investigator Global Assessment success rate significantly higher than placebo. Particularly relevant for women with androgen-driven acne who cannot tolerate or prefer to avoid systemic anti-androgens like spironolactone. Provides targeted anti-androgen activity at the sebaceous gland without the systemic effects, menstrual irregularities, or contraindication in pregnancy associated with oral anti-androgens. Breezula (clascoterone solution 7.5%) has completed Phase 3 clinical trials for androgenetic alopecia in men. Trial results showed improvements in target area hair count compared to vehicle. Regulatory submission is pending. The topical anti-androgen approach offers a potential alternative to systemic 5-alpha reductase inhibitors for men concerned about systemic side effects. The favorable safety profile and lack of systemic anti-androgenic effects make clascoterone a candidate for female androgenetic alopecia, where systemic anti-androgens carry teratogenic risks. Clinical data in women for this indication is still being developed.